Last reviewed · How we verify
Xyzal (LEVOCETIRIZINE)
Xyzal (generic name: LEVOCETIRIZINE) is a Histamine-1 Receptor Antagonist Small molecule drug developed by Sanofi. It is currently FDA-approved (first approved 2007) for Allergic rhinitis, Chronic idiopathic urticaria, Seasonal allergic rhinitis.
Xyzal, also known as levocetirizine, is a small molecule medication used to treat conditions such as seasonal and perennial allergic rhinitis, as well as atopic dermatitis. It is available in oral tablet form and is typically taken once daily.
At a glance
| Generic name | LEVOCETIRIZINE |
|---|---|
| Sponsor | Sanofi |
| Drug class | Histamine-1 Receptor Antagonist |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2007 |
Approved indications
- Allergic rhinitis
- Chronic idiopathic urticaria
- Seasonal allergic rhinitis
Common side effects
- Somnolence
- Nasopharyngitis
- Fatigue
- Dry mouth
- Pharyngitis
- Pyrexia
- Cough
- Epistaxis
- Diarrhea
- Vomiting
- Otitis media
- Constipation
Key clinical trials
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Steroid Use in Treatment of Allergic Reactions to Food (PHASE4)
- Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria (NA)
- Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis (NA)
- Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil (PHASE3)
- COrticosteroids in acUte uRticAria in emerGency dEpartment (PHASE3)
- A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) (PHASE3)
- A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xyzal CI brief — competitive landscape report
- Xyzal updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Xyzal
What is Xyzal?
What is Xyzal used for?
Who makes Xyzal?
What is the generic name of Xyzal?
What drug class is Xyzal in?
When was Xyzal approved?
What development phase is Xyzal in?
What are the side effects of Xyzal?
What does Xyzal target?
Related
- Drug class: All Histamine-1 Receptor Antagonist drugs
- Target: All drugs targeting Histamine H1 receptor
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Chronic idiopathic urticaria
- Indication: Drugs for Seasonal allergic rhinitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing